Anastasia Tararykova

Medical Oncologist | Sarcoma Department | RSG | N.N. Blokhin NMRCO

[Anastasia Tararykova @KisaySol]

#RSG on #ASCO2026

[Anastasia Tararykova @KisaySol]

👏🏻👏🏻👏🏻#asco2026 #sarcoma

[Anastasia Tararykova @KisaySol]

Many thanks to @RobinL_Jones #sarcoma #RSG

[CTOS @ctosociety]

#ARTEMIS-002: #HS20093 is a B7:H3 #ADC demonstrated promising efficacy in #phase 2 #multiple cohorts of #osteosarcomas and #othersarcomas. Dose dependent relationship: 12mg/kg Q3w led to PFS 8.4months, PFSR6 66.6% in previously pre-treated osteosarcoma patients.

[CTOS @ctosociety]

🚨Historical presentation at #CTOS2025
ChonDRAgon - first positive randomised trial in chondrosarcoma
🔹Ozekibart vs placebo
🔹 mPFS 5.52 vs 2.66 months
🔹 HR 0.479; p<0.0001
🔹 a manageable safety profile - most common TRAE: fatigue, diarrhea, and nausea

[Anastasia Tararykova @KisaySol]

Finished our #ESMO25 sarcoma!

[CTOS @ctosociety]

#CTOS2025 Fall Webinar is happening this week!
Join our top-class faculty to learn more about chondrosarcoma!
📆Friday, October 17th, 9.00 AM EST!
You can't miss it!
📷 Registration: https://t.co/8lxfq7H7NH

[Anastasia Tararykova @KisaySol]

Finally arrived! #ESMO25

[Jon Trent, MD, PhD @JTrentMDPhD]

Immunotherapy and Targeted Therapies in #Sarcoma: Proposed Synergy with Combination Treatment @SylvesterCancer @SashaPharmD @GinaDAmatoMD1 @EmilyJonczak @SteveBialickDO @JIPOEditors

https://t.co/oT0zpjBTV8

[Anastasia Tararykova @KisaySol]

Completely happy) #sarcoma #RSG #ASCO2025

[Anastasia Tararykova @KisaySol]

Congratulations #ASCO2025 for staying the best oncology conference. It was a great honor for me to present RSG results and meet dearest colleagues!

[Anastasia Tararykova @KisaySol]

Sometimes a really love my work😅 Best team ever #RSG #sarcoma

[WinetteVanDerGraaf @Winette_vdGraaf]

Agree! Important and nice group to discuss clinical trials and research in #sarcoma @EORTC. And thank you for your support!

[Pawel Sobczuk @pawel_sobczuk]

@FioreDoc discussing changes in new #desmoid treatment guidelines (coming soon) about place of surgery after progression on active surveillance in new guidelines on #desmoid treatment
🔸choose SMART!
#ESMOSarcomaAndRareCancers24
@myESMO @DTRFoundation @sarcomapatients

[Anastasia Tararykova @KisaySol]

Lugano and @eortc 🤍#sarcoma

[Everett Moding, MD, PhD @everettmoding]

Thrilled to share our latest study in @NatureCancer investigating the diverse malignant and stromal cell states that make up soft tissue #sarcomas (STS) and their associations with patient outcomes and response to treatment!
1/12
https://t.co/nwmDAbNHqK

[EHE Foundation @EHEfoundation]

People with #EHE benefit from receiving treatment from multidisciplinary experts experienced in treating #sarcoma. @sarcomapatients / SPAGN is working to help identify this level of expertise for patients.

[Patrick Schöffski @schoffski]

Hard to believe in the era of targeted agents, TKIs, antibodies, immunotherapy and ADCs: the only evidence-based, approved systemic treatment option for liposarcoma (15% of all sarcomas) in 2023 is cytotoxic chemotherapy. Let’s challenge that in 2024! 

[Suzie Siegel @SuzieSiegel]

#Sarcoma specialist Robert Maki @MSKSarcoma did a very well received webinar on the latest #leiomyosarcoma research from #CTOS2023 for https://t.co/p0wVqj5xa9. The link is: https://t.co/Km3USSL5x6 The passcode is: F7!&??5B

[Anastasia Tararykova @KisaySol]

There is my bohemian rhapsody?!?😈 #CTOS2023